throbber
(cid:149) 54
`
`' 1994 Nature Publishing Group http://www.nature.com/naturegenetics
`
`article
`
`Confirmation of BRCAI by
`analysis of germline mutations
`linked to breast and ovarian
`cancer in ten families
`
`Lori S. Friedman, Elizabeth A. Ostermeyer, Csilla I. Szabo, Patrick Dowd, Eric D. Lynch,
`Sarah E. Rowell & Mary-Claire King
`
`We provide genetic evidence supporting the identity of the candidate gene for BRCA1
`through the characterization of germline mutations in 63 breast cancer patients and 10
`ovarian cancer patients in ten families with cancer linked to chromosome 1 7q21. Nine
`different mutations were detected by screening BRCA1 DNA and ANA by single-strand
`conformation polymorphism analysis and direct sequencing. Seven mutations lead to
`protein truncations at sites throughout the gene. One missense mutation (which occurred
`independently in two families) leads to loss of a cystelne in the zinc binding domain. An intmnic
`single basepair substitution destroys an acceptor site and activates a cryptic splice site,
`leading to a 59 basepair insertion and chain termination. The four families with both breast
`and ovarian cancer had chain termination mutations in the N-terminal half of the protein.
`
`Department of
`Molecular d’ Cell
`Biology and School
`of Public Health,
`University of
`California,
`Berkeky, California
`94720, USA
`
`In October 1994, a candidate gene for BRCA1, which is
`responsible for inherited predisposition to breast and
`ovarian cancers in some families, was isolated bypositional
`cloning’. In this report, we confirm that BRCA1 is this
`predisposing gene by analysing germline mutations in the
`families that originally defined the linked phenotype’, as
`well as in other families with breast cancer, and often
`ovarian cancer, linked to chromosome 17q2 1.
`For this purpose, the BRCAI gene was screened using
`single strand conformation polymorphism (SSCP) analysis
`in 20 BRCAI-linlced families, using both genomic DNA
`and cDNA prepared from lysnphoblast RNA. Criteria for
`distinguishing cancer-predisposing mutations from
`polymorphisms in BRCAI were (i) cosegregation of the
`variant with breast cancer, and with ovarian cancer, if it
`appeared; (ii) absence of the variant in control
`chromosomes; and (iii) amino acid substitution in, or
`truncation of, the BRCAI protein encoded by the variant
`sequence.
`
`Detection of mutations in genomic and cDNA
`Primers used to screen genomic DNA and cDNA for
`variation in BRCAI by SSCP analysis are indicated in
`Table 1. All primer pairs were used to screen all 20 families
`by SSCP analysis. Primers flanking exons 2, 3,4 (an Mu
`sequence not found inmost cDNA clones), 5,8,9, 10 and
`12-24 are from the ftp file atmorgan.med.utah.edu’. New
`primers were designed to flank exon 1, which is 100
`basepairs (bp) 5’ of the start site and for which surrounding
`genomic sequence was reported in Genbank (Li 82093) as
`an STS on 17q21 (ref. 3). in order to screen splice junctions
`of exons 6 and 7, intron 6 was sequenced and primers
`defined to yield 200-250 bp amplified products flanking
`Nature Genetics volume 8 december 1994 (cid:9)
`
`exons 6 and 7 independently. Primers were also designed
`to amplify exon 11 in 250-300 bp fragments, using the
`BRCAI cDNA sequence published as Genbank accession
`number U14680 (Table 1). New SSCP primers were
`designed to amplify from cDNA, and are designated
`cl-cl! in Table!.
`Each variant detected by SSCP analysis was sequenced
`using several templates: the variant band from the SSCP
`gel, genomic DNA and/or cDNA from the proband, and
`genomic DNA from family members. The 18 mutations
`(M) or polymorphisms (P) detected in genomic and/or
`cDNA are also indicated in Table 1 next to the primers
`with which each was observed.
`
`Analysis of BRCAI mutations
`Two types of BRCAI variants fulfilling the criteria for
`cancer-predisposing mutations are illustrated by families
`1 and 84. In family 1, an SSCP pattern reflecting a small
`deletion cosegregates with breast and ovarian cancer and
`the BRCA1-linked haplotype (Fig. 1). The haplotype
`analysis predicted that persons #1 and #8 did not inherit the
`linked chromosome, and the mutation analysis confirmed
`their BRCAI sequence was wild type. Thus their breast
`cancers at ages 71 and 45 are sporadic. The variant sequence
`shown has a 2 bp deletion at nucleotides (nts) 2800-2801
`(codon 894), creating a stop at codon 901.
`In family 84, an SSCP pattern representing a single
`nucleotide substitution cosegregates with breast cancer
`and the BRCAI-linked hapiotype (Fig. 2). The variant
`genomic sequence has a thymine to guanine mutation at
`nt 300 of sequence U14680, resulting in a Cys6lGly
`substitution. This mutation removes the penultimate
`cysteine of the putative C3HC4 zinc-binding motif(cid:151)the
`399
`
`GeneDX 1004, pg. 1
`
`

`
`z (cid:9)
`
`co
`
`6 3
`
`’(cid:149) G Zt
`2. 0.
`m a
`. C
`0 (cid:9) (cid:149) 3
`
`.0 OUR
`. ma
`
`(cid:151)
`
`7V 0
`
`.
`
`; (cid:9)
`
`Z
`
`a
`9 (cid:9)
`
`v
`
`-.
`o
`a (cid:9)
`
`00
`3
`
`c.
`8)
`
`o Zp8 (cid:151)
`a> R Lo.
`(9 r..
`
`o 690
`
`Sc
`8) a a
`E 5
`03 gr
`’<:t. Z
`
`0
`2
`C
`3P)3
`
`0
`
`CL -*
`
`Spa
`S
`a
`0)
`
`U,
`
`69
`c c
`- - (cid:151)
`o a:t,
`’9
`-"-lb
`
`r
`
`4.
`
`C a 4.
`
`0
`0-
`1) a
`
`"0
`’0
`
`Primer oair
`exonl
`C
`exon2
`exon3
`c2
`exan4
`exonS
`exon6
`exon7
`c3
`exon8
`c4
`exon9
`axon 10
`exonllAi
`exonilA
`exonllB
`exon1lB2
`exonllC
`exonllD
`exonllD2
`exonhiE
`exon1lE2
`exonlil
`exonhiG
`exonhlH
`e,conlhH2
`exonill
`exonl 112
`exonhli
`exonlll(
`exonllK2
`axon llL
`exonllM
`exonliN
`exonllO
`exonllP
`c5-wonhlPi
`CS
`excn12
`exon13
`c6
`c7
`exon14
`axon 15
`c8
`exon16
`C9
`CIO
`exonl7
`exonh8
`exonl9
`exon20
`cli
`exon2i
`exon22
`exon23
`exon24
`
`Tm (cid:9) Size (bpi 06
`U 14680 bo
`genomic 1-100
`315
`55
`cDNA
`28-280
`55
`253
`101-199
`250
`genomic
`60
`genomic 200-253
`60
`300
`212-530
`55
`319
`cONA
`genomic Alu
`60
`200
`genomic 254-331
`200
`60
`genomic 332-420
`200
`55
`genomic 421-560
`55
`250
`258
`cONA
`390-647
`55
`220
`genomic 561-665
`60
`cDNA
`581-878
`55
`298
`genofnic 666-712
`200
`60
`220
`genomic 713-788
`60
`genomic 789-1090
`55
`301
`858-1166
`309
`both
`55
`1068-1363
`300
`both
`55
`both
`1209-1417
`55
`209
`both
`1299-1593
`55
`295
`1505-1758
`55
`254
`both
`1584-1855
`both
`55
`272
`1716-1985
`269
`both
`55
`1718-2127
`410
`both
`55
`1947-2219
`273
`both
`55
`2142-2460
`55
`319
`both
`2198-2509
`both
`55
`312
`2335-2620
`286
`both
`55
`280
`both
`2485-2764
`55
`2598-2930
`333
`both
`55
`both
`2716-3003
`288
`55
`2897-3201
`55
`305
`both
`both
`2998-3293
`55
`296
`3138-3438
`270
`both
`55
`both
`330-3662
`55
`270
`3552-3804
`both
`55
`253
`3683-3791
`both
`55
`289
`3857-4170
`314
`both
`55
`genomic 4105-4215
`200
`55
`4105-4416
`cDNA
`312
`55
`genomic 4216-4302
`220
`60
`ges’iomic 4303-4476
`280
`60
`287
`cDNA
`4323-4609
`55
`CDNA
`4445-4734
`55
`290
`genotnic 4477-4603
`60
`250
`genomic 4604-4794
`250
`60
`4645-4910
`cDNA
`55
`266
`genomic 4795-5105
`60
`375
`4837-5143
`307
`cDNA
`55
`290
`eDNA
`5092-5381
`55
`genomic 5106-5193
`350
`60
`genomic 5194-5273
`350
`60
`genonuc 5274-5310
`60
`220
`genomic 5311-5396
`220
`60
`cDNA
`5331-5648
`55
`318
`genomic 5397-5451
`60
`275
`genomic 5452-5526
`60
`275
`250
`genomic 5527-5586
`60
`genomic 5587-5711
`60
`275
`
`Forward orhner
`5’- TM CCC ITO OTT TCC GIG -3’
`5 1 - MC MG CTG TOG GOT TIC -3’
`51- GM OTT GTC AlT TTA TM ACC ITT -3’
`5- ICC TGA CAC MC MA CAT hA -3’
`5’- CM GGA ACC TOT CTC CM AM GTG -3’
`5’- GTC MA GM AlA GM TOT GAO C -3’
`5- CTC TTA AGO GCA GIl GIG AG -3’
`5’- CTT ATI hA GTG 1CC VIA MA GO -3’
`5’- CAC MC AM GAG CAT MA TAG GO -3’
`5’- TOT OCT ITT CM CIT GAG ACA 06-3’
`5’- TOT TAG CIG ACT OAT OAT 001 -3’
`5’- CCA ACT CTC TM CCI TOO AM TOT G -3’
`5’- CCA CAG TAO ATG CTC AOl AM IA -3’
`5’- TOG TCA OCT TIC TOT MT CO -3’
`5’- GGA ATT AM IGA 4MG ACT ATG MC -3’
`5’- MC MC ACT GAG MG COT GCA 6-3’
`5’- CM CAT MC MA TOO OCT OGA AC -3’
`5’- CCI MA OAT ACT GM OAT OTT CCI TGG -3’
`5’- GOT TCT OAT GAC TCA CAT OAT 606 -3’
`5’- GM MC CIA TOG GM GM OGC AM -3’
`5’- GAG CCACAOATAATA CAA GAG CGTC-3’
`5 1 - ATC AGO GM CIA ACC AM CGG AG -3’
`5’- TCA 600 MC TM CCA AAC OGA 0-3’
`5’- AGO CTO AGO AGO MO TCT TCT ACC -3’
`5’- OCA ACT GGA 0CC AMMO ACT MC -3’
`5’- CM COA TM ITT CCC MA OCT 0-3’
`5’-AMTGICIAATAATOCTGAM ACC CC-3’
`5’- GCA CTC TAG GGA AGO CM MA CAG -3’
`5 1 - GM GOC ITT MG TAT CCA fIG 06-3’
`5’- 0CC MT CAT ITO CTC COT ITT C -3’
`5’- bC AGO CIT ICC TOT 60110-3’
`5’- OCA AGO AM CTG GM ICA TEA CIC -3’
`5- TCA ATG TCACCT GM MA GM AIG 0-3’
`5’- ITO MT OCT ATG CII MA TEA 6060 -3’
`5’- OTT TOT TCT GAG ACA OCT OAT GACC -3’
`5 1 - GAG TCC TAG CCC TTT CAC CCA TAO -3’
`51 - COT TGO TAC CGA GTG TCT GIC TM 0-3’
`5’- AM 6CC AGO GAO TTG GTC TGA 6-3’
`5’- AM 0CC MG GAG ITO GTC TGA 0-3’
`5’- GTC CTG CCA ATG AGA MA AA -3’
`5-MT OGA AAG CIT CTC AAA GTA ’3’
`5’- CAT MC CTG AlA AAG CTC CAG CM 0-3’
`5’- OCO AM ICC MA ACA MO CAC ATC -3’
`5’- CIA MC TGA ATT ATC ACT ATC A -3’
`5’-TGGCTGCCCACOAAC TAT G-3’
`5’- MA TOO ACA GIT OCT CTG GGA 0-3’
`5’-MTTCT TMCACACACCAGMC-3’
`5’- AIG MC CTG MT CTO ATC CIT CTO -3’
`5’- CCC CM AM MI ITA TOO ICG TO -3’
`5’- GIG TM MC GIG CM OAT 10-3’
`5’- GOC TCT TTA OCT ICI TAG GAG -3’
`5’- CTG TCA TIC TIC CTG TGC IC -3’
`5’- ATA TOA COT GTC TGC TCC AC -3’
`5’- GGA OAT GIG GTC MT GGA MA AAC -3’
`5’- MO CTC TIC CIT ITT GM MT C -3’
`5 1 - ICC CAT IGA GAG GTC ITO CI -3’
`5-CM MC AM MC CTO TCT C -3’
`5’- ATG MT IGA CM TAA TCT CTO C -3’
`
`Revww orimer
`5’-TCA CAA OGCCTTACGCCTC-3’
`5’- TOG ITO MA ACT TIC MC ATG -3’
`5’- TOT CTT TIC TIC CCI AOl ATO 1 -3’
`5’- 116 OAT ITT CGT TCT CM TTA -3’
`5’- AM TCT ITT GOC MG OTT ICT 0-3’
`5’- CCC GTC TCT ACA GM MC AC -3’
`5’- TIC CIA CTO TOO ITO CIT CC -3’
`5’- ITT CAT GGA CAG CAC TIC MT G ’3’
`S’- ICGGCTTCACTCIGT AGAAG-3’
`5’- CGT CIT ITO AGO 116 TAT CCG CTG -3’
`5’- ATC CAG CM TTA TEA hA MT AG -3’
`5’- TOC AGO CU dC ACT GOT OTT C -3’
`5’- TM GM MT MC MC ITC AlA GA -3’
`5’- GTA TCT MC CAC TCT CIT CII CAG -3’
`5’- CTT CCA 0CC CAT CIG ’ETA IGI 10 -3’
`5’-CTC ACA CACOOGATCAGCATTC-3’
`5’- MG ICC MT MA TCA OCT ACT TIG 0-3’
`5’- 0CC ACT MO TCT All TTC TCT GM GM CC ’3’
`5’- TCT GIG OCT CAC TM CM ATG CTC -3’
`5- ICA ICA CII GAG CAT ICT OCT CC -3’
`5’- OCA OAT ICT Ill TOG ACT OAT TCT ATI 660-3’
`5’- CGC ATG MT AIG CCI GOT MA AG
`5’- CCA bA GIl GTA GOT TIC hOC TG -3’
`5’- CAO CTC TOG GM AOl AIC OCT 0-3’
`5’- CCT GAO TGC CAT MT CAG TAG CAG 0-3’
`5’- TCT OTT ITT 6CC TIC CCI MA GIG -3’
`5’- CCC MT OGA TAG TTA AM CCT TCT G -3’
`5’- CAT ICC TCT TCT OCA ITT CCT GO -3’
`5’- CII ATC ITT CTG MC AM CAC MG -3’
`5’- CGT TGC CTC TGA ACT GAO ATO ATAG -3’
`5’- 6CC TM ITO TGC ICA CTG TAG ITO 0 -3’
`5’- MI ACT GGA 6CC CM TIC AlT ACT AC -3’
`5’- CM OAT OCT TAG MT TM TIC CM 0-3’
`5’- GAd OCT TTT OCT AM MC MC AC -3’
`5’- AOl OfF GGA MC AGO GM OCT C 4
`5’-GTOATGTTCCTGAGATGCCTTTG-3’
`5’- MC CCG lid CTC ITT CIT CAT C -3
`5’- GTG CIC CCA MA GCA TM A -3’
`5’- TGA TOG AM GOT MC IGI TAG AM 0-3’
`5’- TOT CM CM ACC TM GM TOT -3’
`5’- ATO ITO GAG CIA GOT CCI TAG -3’
`5’- OAT GAG CII ICC ACT CCT GOT IC -3’
`5’- OCT GTE OCT CCT CCA CAT CM C -3’
`5’- GIG TAT MA TGC dIG TAT GCA .3’
`5’- MC CAO MT ATC ITT ATO TAG GA -3’
`5’- GOT TGA MA TOG TAT OTT 0CC MC -3’
`5- AM ACT CIT ICC MA ATO ITO 1 -3’
`5’- GIG ATO TGG TGT ITT CTO OCA MC 4
`5’- ITC TCT IOC TCG CII TOG MC -3’
`5’-TCGCCT CAT GIGGTIITA-3’
`5’- GM MC AU ITC CCA GCA IC -3’
`5’- CAT TOT TM GOA AM TOO TGC -3’
`5’- 600 MT CCA AAITM ACA GC-3’
`5" IGC TAG ACT GIC CM CAC CCA CTC -3’
`5’- GTAOM AM TAG MT MC CTC T -3’
`5’- GAG MG ACT ICT GAG OCT AC -3’
`5’- ACT OTOCTACTCAAG CAC CA-3’
`5’- GTA 0CC MC MA GIA GM OOA -3’
`
`Variant (by)
`
`14(300). 14(332)
`
`14(300)
`14(332)
`
`P(intron)
`
`PC 1186)
`
`P(2201); P(2430); M(241 5)
`P(2430); 14(2415)
`P(2430); M(241 5)
`P(2430)
`14(2800); 14(2863)
`14(2800); 14(2863)
`
`P(3232)
`P(3232); 14(3238)
`
`P(3667); 14(3726)
`
`14(4184)
`14(4184)
`P(intron)
`
`P(4956)
`P(4956)
`
`P(intron)
`
`14(5677)
`
`S
`
`'
`
`(0
`to
`
`z
`0)
`C
`CD
`-D
`C
`C’
`(4)
`
`(0
`C)
`0
`C
`’C
`
`GeneDX 1004, pg. 2
`
`(cid:9)
`(cid:9)
`

`
`lee YM6 ' 1994 Nature Publishing Group http://www.nature.com/naturegenetics
`
`
`
`Part of Family I
`
`6,71 6,31 7977 6.45 0v48 6r36 (cid:9)
`
`53 (cid:9)
`
`55
`
`’TI 6(cid:243)
`
`Pr 79 IJu1
`T FftiE UEU i I
`
`article
`
`Fig. 1 Framestiift mutation in BRCAI
`linked to breast and ovarian cancer in
`family 1. Symbols under each relative
`Indicate chromosome 17q21
`haplotypes linked (filled rectangles) or
`not linked (open rectangles) to
`BRCAI. Cancers are indicated as
`follows: Br, breast cancer; Ov, ovarian
`cancer; Pr, prostate cancer. Ages at
`diagnosis are also indicated. V
`indicates variant sequence and wt
`indicates wildtype sequence for
`BPCAI, based on SSCP analysis of
`15 relatives, shown below the
`pedigree. The mutant sequence,
`shown on the right, has a 2 bp
`deletion (AA) at nts 2800-2801
`(arrow), leading to a stop at codon
`901. The wild type sequence is
`TCCTrAMGMCAAAGTCCAAAGTC-
`AC1TTTGAATGTGAACA, with the
`mutated sequence underlined.
`
`GATC (cid:9)
`
`appeared twice, in families 84 and 4.
`This mutation probably arose
`independently in the two families,
`because chromosome 17q2 1 marker
`alleles defining the BRCA1 haplotypes
`of the two families differ. The ancestry
`of family 8415 Polish and of family 4
`German; insofar as the families are
`aware, they are not related. The only
`other missense mutation in our
`families leads to the substitution of
`asparagine for serine atcodon 1040 in
`all patients with breast cancer linked
`to BRCA1 in family 14. The functional significance of this
`mutation is currently unknown and might represent either
`a disease-predisposing allele or a rare polymorphism.
`
`Wt (cid:9)
`4 (cid:9)
`
`V
`57
`
`_a (cid:9)
`
`13
`
`t_IJW
` 6r29 49 6r45
`We
`
`T F [ T T (cid:9)
`
`14 4j (cid:9)
`
`6r25 (cid:9)
`
`I T
`
`15 16
`
`6.27 11
`
`I 2 3 4 (cid:9)
`
`5 6 7 $ 9 10 11 (cid:9)
`
`12 13 14 (cid:9)
`
`15
`
`-. -
`
`only recognizable domain so far in the BRCA1 protein.
`Thisvariantdoes notappearin l20 control chromosomes,
`suggesting that it is not simply a rare polymorphism.
`In all, we identified mutations
`cosegregating with breast and ovarian
`cancer and linked to BRCAJ in ten (cid:9)
`families (Table 2). None of these
`mutations has been previously (cid:9)
`observed (D. Goldgar, personal
`communication)’. The ten families
`have nine different mutations: the
`same thymineto guanine substitution
`at nt 300 (the Cys6lGly mutation)
`
`Family84
`
`1
`
`Wt
`
`37 (cid:9)
`
`6r34 (cid:9)
`
`33 (cid:9)
`
`Or 29
`
`EDlEflhl
`
`Wt (cid:9)
`
`V (cid:9)
`
`Wt (cid:9)
`
`V (cid:9)
`
`Fig. 2 Missense mutation in the zinc-binding domain
`of BACA1 linked to breast cancer in Family 84.
`Symbols are as described in Fig. 1; individual #6 had a
`prophylactic mastectomy at age 28, ten years prior to
`entrance into the study. The mutant sequence, shown
`on the right, illustrates the Ito G substitution at nt 300
`(arrow), which leads to replacement of the penultimate
`Cys in the zinc binding domain with a Gly residue. This
`Cys6l Gly mutation also occurred, probably
`Independently, in Family 4. The wild type sequence Is
`GCTGAAACTrCTCAACCAGAAGW-
`GGGccTrcAcAGTGIGTCCmATGTAAGAATGATATA-
`ACCMAAGGTAT, with the mutated sequence
`underlined.
`
`Or SS
`
`Or 55
`
`ILU
`1 (cid:9)
`
`Or 32,37 pm 28
`
`V (cid:9)
`
`Wt
`
`G AIC
`
`a
`
`- a
`-a--
`
`12 345678
`
`.-.
`
`Nature Genetics volume 8 december 1994 (cid:9)
`
`401
`
`GeneDX 1004, pg. 3
`
`(cid:9)
`(cid:9)
`(cid:9)
`

`
`article
`
`U
`
`' 1994 Nature Publishing Group http://www.nature.com/naturegenetics
`
`
`
`Table 2. Gesmllno mutations cosegregating with breast and ovarian cancer In BRCAI-linked families
`
`Family ARCA1 nt (cid:9)
`4
`300
`84
`300
`332
`82
`2415
`3
`1
`2800
`102
`2863
`14
`3238
`74
`3726
`2
`4184
`77
`5677
`
`Exon
`5
`5
`Intron 5
`11
`11
`11
`11
`11
`11
`24
`
`Mutation
`Ito G substitution (rGT-i.GGT)
`T to G substitution (TGT-*GGT)
`Ito 0 substitution-+59 bp insertion
`AG deletion
`AA deletion
`TO deletion
`GtoAsubstitution (AGC-+AAC)
`C to T substitution (CGA.-+TGA)
`ICAA deletion
`A insertion
`
`Amino acid change (cid:9)
`Cys61 Gly
`Cys6l Gly
`75Stop
`Ser766Stop
`901Stop
`Ser915Stop
`SerlO4OAsn
`Argl 2O3Stop
`1 364Stop
`Iyrl853Stop
`
`Predicted effect
`lose zinc-binding motif
`lose zinc-binding motif
`protein truncation
`protein truncation
`protein truncation
`protein truncation
`missense
`protein truncation
`protein truncation
`protein truncation
`
`Table 2b Sites, ages at diagnosis and lateral lty of cancers associated with BRCAI mutations
`
`Family
`
`4
`84
`82
`3
`1
`102
`14
`74
`2
`77
`
`Breast cancer (cid:9)
`llateral) Avg. age at dx (cid:9)
`Cases (cid:9)
`10(1)
`39.7
`5(1)
`41.6
`40.3 (cid:9)
`6(2)
`3 (0)
`37.3 (cid:9)
`16(0)
`37.8 (cid:9)
`45.2 (cid:9)
`5(0)
`51.1
`6(2)
`6 (1)
`45.5
`38.2
`5(1)
`7(1)
`32.9
`
`Ovarian cancer
`Avg. age at dx
`Cases (cid:9)
`
`Other cancers with with BRCAI mutations
`
`2 (cid:9)
`4 (cid:9)
`2 (cid:9)
`3 (cid:9)
`
`52.1
`46.3
`54.5
`51.7
`
`Small Intestine (dx 46)
`
`3 Prostate (dx 57, 77, 79)
`
`KIdney (dx 55); Colon (dx. 40)
`
`However, we have not found the mutation in 120 control
`chromosomes.
`The remaining seven mutations all lead to truncated
`proteins, mostly due to small insertions or deletions of 1
`to 4 bp (Table 2). Four mutations are immediate stops; the
`others are frameshifts leading to stops after 4, 7 and 9
`codons, respectively. In family 3, one AG doublet is
`deleted from an (AG) 3 repeat; the other small length
`changes appeared to be random throughout the sequence.
`In family 82, a thymine to guanine substitution occurs
`s(cid:231) of the exon 6 splice
`within the consensus sequence
`acceptor site (Fig. 3). This substitution leads to the
`preferential activation in intron 5 of a cryptic splice
`acceptor’. This generates a mutant transcript containing
`
`a 59 bp insertion of intronic sequences’ of exon 6, causing
`a stop at codon 75. Both the wild type and mutant
`transcripts are detected in lymphocyte cDNA with primer
`pair c2.
`One variant observed only at the cDNA level could not
`yet be classified as apredisposing mutation. In two patients
`from family 5 with BRCA1-linked breast and ovarian
`cancer, cDNA prepared from lymphoblast RNA lacked
`exon 3. (No RNA from breast tumour is available for this
`family.) Exon 3 splice junction sequences are normal in
`genomic DNA from these patients. The absence of exon 3
`has not been observed in lymphoblast cDNA from controls
`or from other breast cancer families. This case differs from
`the family 82 variant in that in family 5, an entire exon is
`
`Family 82
`
`6 (cid:9)
`
`84
`
`8,47
`
`8,43 (cid:9)
`
`16
`
`0v54
`
`Wt
`
`Wt
`
`Wt
`
`v
`
`Wt
`
`8,42,47 OvSI 41 (cid:9)
`
`45
`
`47 (cid:9)
`
`44 ntiS
`
`47
`
`8r29,33
`
`v (cid:9)
`
`v
`
`Wt (cid:9) Wt
`
`Wt
`
`M
`
`Wt
`
`Y
`
`Exon 5
`
`Exon 6
`
`...NNNNNcTFATTVFAGTG .........ACAAGrrAA1TrCAGGA. (cid:9)
`A
`ACMTrFAXVVFCAGGA (cid:9)
`
`Family 82 mutation
`
`Wild type acceptor
`
`402 (cid:9)
`
`Fig. 3 Aberrant splicing leading to a
`truncated 6RCA1 protein in Family 82.
`a, BRCAI-Iinked patients and
`unaffected relatives of Family 82. Mutant
`) or wildtype (wi) sequence was
`confirmed In living relatives. (Symbols
`are as given inFig. 1). b, Aberrant
`splicing of exons 5 and 6 In Family 82. A
`cryptic splice acceptor site In Intron 5
`(open box) leads to insertion of 59 bp
`(hatched box) into the mutant transcript
`Sequences of exons Sand 6 (filled
`boxes) are normal. The cryptic acceptor
`is activated by a T to substitution in
`the usual acceptor site. The concensus
`splice acceptor sequence is
`(Py)32NCAG/N.
`
`Nature Genetics volume 8 december 1994
`
`GeneDX 1004, pg. 4
`
`(cid:9)
`(cid:9)
`

`
`1;T8 IN ' 1994 Nature Publishing Group http://www.nature.com/naturegenetics
`
`article
`
`BRCA 1 nt
`intron 8
`1186
`2201
`2430
`3232
`3667
`intron 12
`4956
`intron 16 or 17
`
`Nucleotide variant
`T deleted
`A/G
`CIT
`TIC
`A’G
`A/G
`CA deleted
`A/G
`not sequenced
`
`Amino acid variant
`non-coding
`Gln356Arg
`silent
`silent
`Glu1038Gly
`Lysll83Arg
`non-coding
`Sen 61 3Gly
`non-coding
`
`.671.33 (cid:9)
`.671.33 (cid:9)
`.67433 (cid:9)
`.9505 (cid:9)
`
`69/31 (cid:9)
`
`associated with veryearly-onset breast
`Table 3 Neutral polymorphisms in BRCAI
`cancer in family 77. Bilateral breast
`Allele frequencies cancer was associated with mutations
`throughout the sequence, although
`67/33 (cid:9)
`ascertainment of bilaterality is biased
`:82/13 (cid:9)
`in veryhigh-risk families in that some
`women choose bilateral mastectomy
`following their first diagnosis ofbreast
`cancer. In this series, there is no
`association between age at onset and
`locale or type of mutation, but these
`families were selected for early age at
`breast cancer diagnosis and probably
`do not represent BRCA1 patients
`generally. Better evaluation of outcomes associated with
`BRCAJ mutations of different types and at different
`locations in the sequence will be based on identifying
`germline BR CAI mutations in population-based series of
`cases not selected for family history.
`The mutations found, andnot found, in these 20 families
`illustrate the complexities ofscreening for inherited BRCA1
`mutations in families, let alone in the general population 6’7.
`First, mutationswere identified inonly5o% ofthe families
`in this series, although both genomic DNA and RNA were
`screenedby SSCP analysis and all families have convincing
`evidence of BRCA1 linkage’,’. The families for which
`BRCA1 mutations have not yet been identified are as
`likely to carry mutations as those successfully screened.
`The posterior probability of linkage is ~!.95 for families
`with and without definable mutations. The two groups of
`families are similar in number and ages at diagnosis of
`breast and ovarian cancers linked to BRCA1; ovarian
`cancer occurred in four of ten families with mutations
`found and in five of ten families with mutations still
`undetected. Additional mutations may prove detectable
`by other screening techniques such as mismatch cleavage
`analysis, or by Southern or northern hybridization.
`However, it is likely that a large fraction of mutations will
`only be detectable when genomic sequence of the entire
`gene is available. The importance of genomic sequence is
`illustrated by the successful detection of two mutations in
`cDNA: the 59 bp intronic insertion in family 82 reported
`here and the loss of transcript in family 2035 previously
`described’. The intronic mutation leading to aberrant
`splicing in family82 could onlybe identified from genomic
`sequence. In general, mutations in introns and promoter
`regions can only be identified reliably when sequence of
`the entire 80 kb BRCAI gene is known and critical regions
`identified therein. The alternative would be to screen
`breast or ovarian RNA for mutations using multiple
`techniques, an approach not feasible on a wide scale.
`Second, most BRCAI variants are not predisposing
`mutations. Most individuals, including women at high
`risk of breast cancer, are heterozygous at one or more sites
`in the BRCA1 gene. Most of these variants are
`polymorphisms, some of which will be revealed, after
`sequencing, to be noncoding or silent. However, in this
`series, four missense mutations were revealed that altered
`peptide sequence. Because they occurred at similar
`frequencies in cases and controls, we concluded that they
`are polymorphisms. Even by screening cases and controls,
`some rare polymorphisms may be mistakenly identified
`as predisposing mutations. The mutation at nt 3238 in
`family 14 may prove to be of this type, and we would not
`predict risk for an asymptomatic woman based on that
`403
`
`missing and no intronic sequence has been introduced. It
`is possible that absence of exon 3 represents alternative
`splicing characteristic of lyrnphoblasts we immortalized
`for this family, rather than having any relationship to
`cancer predisposition. Alternatively, an inherited mutation
`in genomic DNA leading to consistent aberrant splicing
`would strongly suggest that the variant is disease-related.
`
`BRCAI polymorphisms
`Nine polymorphisms were detected in BRCAJ, six in the
`coding sequence and three in introns (Table 3). Four
`polymorphisms alter amino acid residues. Five
`polymorphisms are in complete disequilibrium with each
`other, and a sixth is in partial disequilibrium, based on
`genotypes of 42 chromosomes. Identification of these
`polymorphisms enabled us to screen for mutations causing
`loss of BRCAI transcript in the ten families for which no
`mutations were found bySSCP analysis of genomic DNA
`and cDNA.
`Genomic DNAs from probands of these families were
`genotyped for polymorphisms in the BRCA1 coding
`sequence. Probands of five families with undetected
`mutations were heterozygous for one or more
`polymorphisms. The cDNAofthese five probands were also
`heterozygous, indicating that mRNA was being expressed
`from both BR CAl alleles. For the remaining five families,
`patients heterozygous for coding sequence polymorphisms
`will be identified and the same test carried out
`
`Discussion
`Most of the BRCA1 mutations we have identified result in
`premature termination of protein translation. Such
`truncated proteins could conceivably compete with
`wildtype protein, thereby acting as dominant mutations.
`On the other hand, loss of the wildtype allele in the
`tumours of patients with BRCAI germline mutations
`would suggest the opposite role - that the termination
`mutation was recessive. Paraffin blocks with adequate
`malignant cells for loss-of-heterozygosity (LOH) studies
`were available for one tumour from family 1, five tumours
`from family 3 and two tumours from family 82. For all
`eight of these tumors, the wildtype BRCA1 allele was lost,
`an observation consistent with recessive mutations 5.
`The number of families with BRCAI mutations
`identified is still very small, so associations between
`genotype and phenotype are not at all certain. Cancer-
`related mutations occur throughout the BRCA1 sequence
`(Table 2). In our series, all four families with both ovarian
`and breast cancer had truncation mutations in the first
`half of the protein. However, termination of the BRCA1
`protein only 11 amino acids from the C-terminal end was
`Nature Genetics volume 8 december 1994 (cid:9)
`
`GeneDX 1004, pg. 5
`
`(cid:9)
`

`
`' 1994 Nature Publishing Group http://www.nature.com/naturegenetics
`
`
`
`article
`
`mutation without determining its biological function.
`Third, there are many predisposing mutations in
`BRCAJ, and the risks associated with most are notknown.
`The mutations identified so far have high penetrance,
`because they were identified in families ascertained for
`very high lifetime risk of breast cancer. Whether other
`BRCA1 mutations are associated with more moderate
`risk, possibly influenced by other genetic or
`environmental factors, remains to be seen.
`
`Methodology
`SSCP. PCR was carried out in 50 jil volumes containing 50 ng
`cDNA or genomic DNA, lx PCR buffer (Boehringer Mannheim),
`200 p dATP, dGTP, dITP (BoehringerMannheim), 1O PM dCTP
`(Boehringer Mannheim), 50 pmoles each primer from Table I
`(Operon), 05 pCi 32P-dCTP (NEN Dupont), 1.25 U Taq DNA
`polymerase (Boehringer Mannheim). PCR conditions for primer
`(Tm from
`pairs were 35 cycles of 94 (cid:176)C, 45 s annealing temperature
`Table 1) 305; 72 ’C; 30 s. PCR template was lymphocyte cDNA or
`genomic DNA from members of BRCA 1-linked families who carry
`the predisposing haplotype. Amplified samples were diluted 1:10 in
`formamide buffer (98% formamide, 10 mM EDTA pH 8,0.05%
`Bromophenol blue, 0.05% Xylene cyanol), held at 95(cid:176)C for 5 mm,
`then cooled rapidly to 4(cid:176)C. and held for 5 mm. For each sample, 5
`p1 was loaded onto an SSCP gel and run at W (constant power) for
`16 h in 0.6x TBE at room temperature. (An 80 ml gel solution
`contains: 0.5x MDE (AT Biochem), 0.6x TBE, 160 0 25%
`ammonium persulphate, 38 p1 TEMED.) Gels were dried on a
`
`Received 8 November; accepted 9 November 1994.
`
`vacuum gel dryer and exposed to film for 12-24h with an intensifying
`screen. Variant bands were cut out of the gel and rehydrated in 100
`p1 water.
`
`Sequencing. PCR was carried out in 50 0 volumes containing 50 n
`DNA or cDNA or I p1 of rehydrated SSCP gel fragment solution, lx
`PCR buffer (Boehringer Mannheim), 200 ;LM dATP, dCTP, dITP,
`dGTP (BoehringerMannheim), 1.25 U Taqpolymerase(Boehringer
`Mannheim), 50 pmoles each primer (Operon) that detected the
`SSCP variant Cycling conditions were 35 cycles of 94 ’C, 45 s,
`annealing temperature (Tm in Table 1) 30 s, 72 ’C, 30 s. Direct
`sequencingofthedouble-stranded DNA from the PCRamplification
`was performed with the USB PCR product sequencing kit, using (cid:176)S
`ATP as the isotope. Sequencing primers were the same as those used
`to amplify thetemplate. Sequence was run on 6% acrylamide/bis gels
`at 70 Wconstant power for 2 h, and exposed to X-ray film for 12-24
`h. Mutations were confirmed in multiple members of each familyby
`amplifying and directly sequencing from genomic DNA.
`Intron 6 sequence was obtained by amplifying genomic DNA
`using the primer pair axon 6&7 (ftp file at morgan.med.utah.edu ),
`with the reaction mixture described above. Direct sequencing was
`done on the 800 bp product as described above.
`
`Acknowldg.ments
`This work was supported in part by NIH grant ROl CA27632. L.S.F.
`is aKomen Foundation Fellow; C.I.S. is an NIH Fellow; M-C.K. is an
`American Cancer Society Professor.
`
`1. Mild, Y. stal. A strong candidate forthe breast and ovarian cancer susceptibility
`gene BRCA1. Science 266 66-71 (1994).
`2. Hat. J.M. eta). Unkage of early-onset familial breast cancer to chromosome
`17q21. Science 260, 16W1689(1990).
`3. Albertson, N.M. at at A physical map and candidate genes In the BRCAI
`region on chromosome 17q12-21. Nature Canal. 7, 472-479 (1994).
`4. Sharp, P.A. Split genes and ANA splicing. Cell 77, 805-815 (1994).
`5. Friedman, L.S. eta). The search for BRCA1 and the cloning of 22 genes from
`
`chromosome 17q21. Cancer Ass. Qn the press).
`8. American Society of Human Genetics. Statement on genetic testing for
`breast and ovarian cancer. Am. J. hum. Genet 56,860(1994).
`7. ROWalI, S., Newman, B.. Boyd, J. & King, M-C. Inherited predisposition to
`breast and ovarian cancer. Am. J. hum. Genel 56,881-885(1994).
`8. Arena, J.F. etaL Inherited breast cancer: Confirmation of lInkage to BRCA2,
`possible linkage to the estrogen receptor, and the clinical Implications of
`genetic complexity. J. Am. med. Assoc. (In the press).
`
`404 (cid:9)
`
`Nature Genetics volume 8 december 1994
`
`GeneDX 1004, pg. 6

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket